As a 31-amino acid analogue of native GLP-1 with a C18 fatty diacid chain attached at position Lys via a gamma-glutamic acid/mini-PEG linker, semaglutide achieves a plasma half-life of approximately 7 days in humans the longest of any GLP-1R agonist through albumin binding and resistance to DPP-IV degradation

Warning signs that need medical attention Seek medical evaluation within 24 to 48 hours if you experience: Redness that continues expanding beyond 48 hours after injection Redness diameter exceeding 10 centimeters Increasing pain (not decreasing) after 48 hours Warmth and hardness accompanied by fever above 100.4 F (38 C) Pus, drainage, or fluid oozing from the injection site Red streaks extending outward from the injection site (sign of lymphangitis) Reaction that has not shown any improvement after 7 days Seek emergency medical care immediately if you experience: Hives or rash spreading beyond the injection site to other body areas Swelling of the face, lips, tongue, or throat Difficulty breathing, wheezing, or shortness of breath Dizziness, lightheadedness, or feeling faint Rapid heartbeat Severe abdominal pain These emergency symptoms suggest a systemic allergic reaction (anaphylaxis), which is rare but documented with tirzepatide
Jessica Bartlett can be reached at [email protected]
Baseline body weight and composition matter significantly: individuals with higher starting weights often experience faster absolute pound loss in early months, though percentage loss may be similar across weight categories
We identified 1,209 records through a comprehensive literature search